{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ02376",
      "entity_text" : "hFIX",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-1108" ],
      "CellType" : [ "cl:CL:0000084" ],
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "At the highest dose, in the first subject dosed from this cohort, 8 weeks post-infusion the therapeutic hFIX levels (approximately 8-10% of normal) started to decline and, similarly to the previous trial, an elevation of liver enzymes and an increase in circulating capsid specific T cells was detected.",
  "reading_complete" : "2020-08-04T11:18:22Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T11:15:48Z",
  "trigger" : "levels",
  "evidence" : [ "hFIX levels" ],
  "pmc_id" : "7181373",
  "score" : 0
}